ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.
What happened
FDA reviewed ASN-LABS's website at https://asn-labs.com in August 2025, not an inspection. The site offered compounded drug products including retatrutide and semaglutide. FDA said retatrutide products were unapproved and misbranded, and semaglutide claims falsely implied the products were the same as FDA-approved Wegovy and Ozempic.
What FDA found
The compounded retatrutide products are unapproved new drugs because no FDA-approved application is in effect for them.
FDCA sections 505(a) and 301(d) [21 U.S.C. §§ 355(a), 331(d)]The retatrutide products are misbranded because their labeling lacks adequate directions for use.
FDCA sections 502(f)(1) and 301(a) [21 U.S.C. §§ 352(f)(1), 331(a)]The retatrutide products do not qualify for 503A or 503B compounding exemptions because retatrutide is not on the 503A or 503B bulks lists and is not an approved drug component or on the shortage list.
FDCA sections 503A(b)(1)(A)(i) and 503B(a)(2)(A)(i) [21 U.S.C. §§ 353a(b)(1)(A)(i), 353b(a)(2)(A)(i)]The website claims that compounded semaglutide has the same active ingredient as Wegovy and Ozempic and is the generic drug in those products are false or misleading because compounded drugs are not FDA-approved.
FDCA sections 502(a), 502(bb), and 301(a) [21 U.S.C. §§ 352(a), 352(bb), 331(a)]
What FDA wants
FDA tells ASN-LABS to take immediate action, including ceasing the misleading semaglutide language, and to send a written response within 15 working days describing specific steps taken, documentation, and how it will prevent recurrence.
Who should pay attention
- telehealth and online pharmacy operators
- compounding pharmacies and outsourcing facilities
- companies marketing compounded semaglutide or retatrutide
This is a summary. Read the original letter on fda.gov.